Skip to search formSkip to main contentSkip to account menu

AZD 0530

Known as: AZD-0530, AZD0530 
An orally available 5-, 7-substituted anilinoquinazoline with anti-invasive and anti-tumor activities. AZD0530 is a dual-specific inhibitor of Src… 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

saracatinib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
A randomized placebo-controlled trial of saracatinib (AZD0530) plus weekly paclitaxel in platinum-resistant ovarian, fallopian-tube, or primary peritoneal cancer (SaPPrOC)
5514 Background: Weekly paclitaxel (wPxl) has activity in platinum-resistant ovarian cancer (PROC). Upregulated Src kinase… 
2012
2012
Modulation of epithelial tight junctions by TGF-beta 3 in cultured oral epithelial cells.
BACKGROUND Previous studies have indicated that transforming growth factor beta 3 (TGF-β3) was strongly expressed both in the… 
Highly Cited
2011
Highly Cited
2011
Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo
Antiestrogen therapies arrest susceptible estrogen receptor (ER)-positive breast cancers by increasing p27. Since Src… 
Review
2011
Review
2011
The integrin signalling adaptor p130CAS is also a key player in prostate cancer
In a recent Review article (Integrin signalling adaptors: not only figurants in the cancer story. Nature Rev. Cancer 10, 858–870… 
2010
2010
A phase II trial of saracatinib (AZD0530), an oral Src inhibitor, in previously treated metastatic pancreatic cancer.
e14515 Background: Src family tyrosine kinases are overexpressed in pancreatic cancers, and the oral Src inhibitor saracatinib… 
2010
2010
A randomized phase II clinical trial of the SRC inhibitor saracatinib (AZD0530) and carboplatin plus paclitaxel (C plus P) versus C plus P in patients (pts) wiht advanced platinum-sensitive…
2009
2009
Improved Response by Co-targeting EGFR/EGFRvIII and Src Family Kinases in Human Cancer Cells
We hypothesized that co-targeting the epidermal growth factor receptor (EGFR) and Src with the EGFR inhibitor gefitinib and the… 
2008
2008
Combined Inhibition of cSrc and Epidermal Growth Factor ReceptorAbrogates Growth and Invasion of Head and Neck Squamous Cell Carcinoma
Purpose: Increased expression and/or activation of epidermal growth factor receptor (EGFR) is associatedwith tumor progression… 
2005
2005
Phase I ascending single and multiple dose studies to assess the safety, tolerability and pharmacokinetics of AZD0530, a highly selective, dual-specific Src-Abl inhibitor
3125 Background: AZD0530 is a highly selective, dual-specific, orally available, small molecule inhibitor of Src kinase and Bcr… 
2005
2005
The effect of AZD0530, a highly selective, orally available Src/Abl kinase inhibitor, on biomarkers of bone resorption in healthy males
3041 Background: AZD0530 is a highly selective, dual-specific, orally available small molecule inhibitor of Src kinase and Bcr… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)